The Measurable Residual Disease (MRD) Testing Implementation Roadmap for B-cell Acute Lymphoblastic Leukemia (ALL) is an innovative learning tool that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain MRD testing for patients with adult B-cell ALL. This Roadmap will give healthcare professionals information about how to lay the groundwork for MRD testing, train and prepare their care team to offer testing, implement testing, and evaluate ongoing progress. “Expert Insights” from the Advisory Committee that informed the Roadmap give teams a deeper understanding of how MRD testing fits into their cancer program. Online pre- and post-assessments in the Roadmap allow teams to gauge their progress in implementing MRD testing for their patients.
Resources from the four sections of the Implementation Roadmap provide more information and are available in the Resource Library. The color-coded boxes in the Resource Library match the Roadmap journey, making it easy to find relevant resources quickly.